209 related articles for article (PubMed ID: 22205272)
21. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
22. Treatment, management, and monitoring of established rheumatoid arthritis.
Bingham CO; Miner MM
J Fam Pract; 2007 Oct; 56(10 Suppl Rapid):S1-7; quiz S8. PubMed ID: 17949607
[No Abstract] [Full Text] [Related]
23. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.
Chu DH; Van Voorhees AS; Rosenbach M
Arch Dermatol; 2011 Oct; 147(10):1228-30. PubMed ID: 22006150
[No Abstract] [Full Text] [Related]
24. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
25. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
[TBL] [Abstract][Full Text] [Related]
26. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Aranda R; Becker JC; Nys M; le Bars M; Reed DM; Poncet C; Dougados M
Ann Rheum Dis; 2011 Nov; 70(11):2003-7. PubMed ID: 21914628
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
28. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Krüger K
Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
[TBL] [Abstract][Full Text] [Related]
29. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.
Nishimura K; Saegusa J; Kawano S; Morinobu A
J Rheumatol; 2012 Sep; 39(9):1904-5. PubMed ID: 22942311
[No Abstract] [Full Text] [Related]
31. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
32. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
[No Abstract] [Full Text] [Related]
33. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
[TBL] [Abstract][Full Text] [Related]
34. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
35. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
36. Relative efficacies: antimalarials to abatacept - the choice is ours.
Russell AS
J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
38. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
[TBL] [Abstract][Full Text] [Related]
39. Abatacept: a novel treatment for rheumatoid arthritis.
Lundquist LM
Expert Opin Pharmacother; 2007 Oct; 8(14):2371-9. PubMed ID: 17927490
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]